
Jochen Büchner
- Senior consultant; PhD
Publications 2021
Correction: ABO incompatibile graft management in pediatric transplantation
Bone Marrow Transplant, 56 (1), 297
DOI 10.1038/s41409-020-01012-z, PubMed 32753704
Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3
Cancer Genomics Proteomics, 18 (1), 67-81
DOI 10.21873/cgp.20242, PubMed 33419897
Publications 2020
ABO incompatibile graft management in pediatric transplantation
Bone Marrow Transplant, 56 (1), 84-90
DOI 10.1111/j.1537-2995.2011.03295.x, PubMed 32594103
Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplant, 55 (6), 1126-1136
DOI 10.1111/bcp.13322, PubMed 32029909
Correction: Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplant, 55 (6), 1214
DOI 10.1038/s41409-020-0838-0, PubMed 32080355
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
J Clin Oncol, JCO2002529 (in press)
DOI 10.1200/JCO.20.02529, PubMed 33332189
Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency
Front Immunol, 11, 1417
DOI 10.3389/fimmu.2020.01417, PubMed 32754152
Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study
Bone Marrow Transplant, 55 (8), 1540-1551
DOI 10.1038/s41409-020-0854-0, PubMed 32203263
Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Clin Cancer Res, 27 (2), 575-584
DOI 10.1158/1078-0432.CCR-20-2574, PubMed 33082212
Publications 2019
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients
Cells, 8 (12)
DOI 10.3390/cells8121577, PubMed 31817480
Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience
Br J Haematol, 184 (6), 982-993
DOI 10.1111/bjh.15761, PubMed 30680711
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
Lancet Oncol, 20 (12), 1710-1718
DOI 10.1016/S1470-2045(19)30493-0, PubMed 31606419
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children
Eur J Cancer, 110, 74-85
DOI 10.1016/j.ejca.2019.01.013, PubMed 30772656
Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells
Aging Cell, 18 (2), e12897
DOI 10.1111/acel.12897, PubMed 30712319
Publications 2018
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)
Bone Marrow Transplant, 53 (7), 852-862
DOI 10.1038/s41409-018-0102-z, PubMed 29379171
Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe
Hemasphere, 2 (1), e18
DOI 10.1097/HS9.0000000000000018, PubMed 31723747
Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway
Bone Marrow Transplant, 53 (5), 657-660
DOI 10.1038/s41409-018-0091-y, PubMed 29358600
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
N Engl J Med, 378 (5), 439-448
DOI 10.1056/NEJMoa1709866, PubMed 29385370
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Nat Med, 24 (10), 1504-1506
DOI 10.1038/s41591-018-0146-z, PubMed 30275569
Publications 2017
Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders
J Allergy Clin Immunol, 141 (1), 322-328.e10
DOI 10.1016/j.jaci.2017.02.036, PubMed 28392333
Publications 2016
Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007
Cancer Med, 5 (8), 1765-75
DOI 10.1002/cam4.741, PubMed 27228363
Publications 2013
Fusion of ZMYND8 and RELA genes in acute erythroid leukemia
PLoS One, 8 (5), e63663
DOI 10.1371/journal.pone.0063663, PubMed 23667654
Publications 2012
N-myc and noncoding RNAs in neuroblastoma
Mol Cancer Res, 10 (10), 1243-53
DOI 10.1158/1541-7786.MCR-12-0244, PubMed 22936790
Publications 2011
MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma
Carcinogenesis, 32 (7), 1005-12
DOI 10.1093/carcin/bgr073, PubMed 21572098
Inhibition of gene function in mammalian cells using short-hairpin RNA (shRNA)
Methods Mol Biol, 703, 189-204
DOI 10.1007/978-1-59745-248-9_13, PubMed 21125491
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
BMC Dev Biol, 11, 1
DOI 10.1186/1471-213X-11-1, PubMed 21194500
Publications 2010
Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells
Differentiation, 81 (1), 25-34
DOI 10.1016/j.diff.2010.09.184, PubMed 20980091
Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria
Hum Mutat, 31 (3), 279-83
DOI 10.1002/humu.21186, PubMed 20020533
Publications 2009
Ewing sarcoma-peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript
Cancer Genet Cytogenet, 194 (1), 53-7
DOI 10.1016/j.cancergencyto.2009.06.002, PubMed 19737655
Publications 2003
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
Nat Genet, 34 (2), 148-50
DOI 10.1038/ng1156, PubMed 12717436